A twenty year old female was referred to hospital by her GP, after he received the results of blood tests taken earlier in the day. She had presented to him complaining of malaise, nausea and anorexia over a 3 day period. On the day of referral she had also become jaundiced with dark urine, but normal stool colour. There was no abdominal pain. She had no significant past medical history with no history of jaundice, liver disease or autoimmune conditions, and no apparent risk factors for blood-borne hepatitis infection. There was no relevant family history. She was taking no prescribed medication, had not taken any over the counter medication or herbal remedies. She denied excessive alcohol use or use of intravenous drugs in the past, although she was not specifically questioned on the use of other recreational drugs. She was a single mother and admitted to being under considerable stress recently. On examination she appeared well, apart from marked jaundice. There were no signs of hepatic encephalopathy or chronic liver disease. Abdominal examination revealed mild left upper quadrant tenderness, but no significant hepatomegaly. Liver function tests (LFTs) taken by her GP are shown in Table 1, revealing marked elevation of the Alanine Transaminase (ALT) (Table 1), with a relatively preserved albumin. Unfortunately her International Normalised Ratio (INR) had not been measured. An Ultrasound of the abdomen demonstrated a normal size liver with normal contour and texture with no other abnormality.
[download-attachments container="div" style="list" dipslay_icon="1" display_count="1" display__size="0"]

References

1. Andreu V, Mas A, Bruguera M, Salmeron JM, Moreno V, Nogue S et al. Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol 1998; 29(3):394-397.
2. De CL, De GA, Slim AO, Giacomoni A, Corti A, Mazza E et al. Liver transplantation for ecstasy-induced fulminant hepatic failure. Transplant Proc 2001; 33(5):2743-2744.
3. Ellis AJ, Wendon JA, Portmann B, Williams R. Acute liver damage and ecstasy ingestion. Gut 1996; 38(3):454-458.
4. Garbino J, Henry JA, Mentha G, Romand JA. Ecstasy ingestion and fulminant hepatic failure: liver transplantation to be considered as a last therapeutic option. Vet Hum Toxicol 2001; 43(2):99-102.
5. Pereira SP, McCarthy M, Ellis AJ, Wendon J, Portmann B, Rela M et al. Auxiliary partial orthotopic liver transplantation for acute liver failure. J Hepatol 1997; 26(5):1010-1017.
6. Smith ID, Simpson KJ, Garden OJ, Wigmore SJ. Non-paracetamol druginduced fulminant hepatic failure among adults in Scotland. Eur J Gastroenterol Hepatol 2005; 17(2):161-167.
7. Khakoo SI, Coles CJ, Armstrong JS, Barry RE. Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymetamphetamine ("ecstasy") usage. J Clin Gastroenterol 1995; 20(3):244-247.
8. Wu D, Otton SV, Inaba T, Kalow W, Sellers EM. Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 1997; 53(11):1605-1612.
9. Brosen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36(6):537-547.
10. Gonzalez FJ, Meyer UA. Molecular genetics of the debrisoquin-sparteine polymorphism. Clin Pharmacol Ther 1991; 50(3):233-238.
11. Fidler H, Dhillon A, Gertner D, Burroughs A. Chronic ecstasy (3,4- methylenedioxymetamphetamine) abuse: a recurrent and unpredictable cause of severe acute hepatitis. J Hepatol 1996; 25(4):563-566.
12. Jones AL, Simpson KJ. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol Ther 1999; 13(2):129-133.